The total costs of dementia are anticipated to be $818 billion in 2026, driven by quality-of-life losses for persons with dementia and care partners, according ...

The expanded indication makes risankizumab the first IL-23 inhibitor available for pediatric patients weighing under 40kg with plaque psoriasis or psoriatic arthritis, supported by phase 3 OptIMMize ...

Backed by data from the phase 3 SatraGO trials, satralizumab has the potential to offer patients a convenient, at-home treatment option.

For ifosfamide, used to treat sarcomas, lymphomas and testicular cancers, some doctors are already meeting to decide who gets treated.

The letter focuses exclusively on manufacturing control strategies for the biological component and contract manufacturing facility deficiencies. The Food and Drug Administration (FDA) has issued a ...

The new presentation is expected to provide an additional self-administration option for patients with polycythemia vera.

The FDA has approved an expanded indication for Zoryve (roflumilast) cream 0.3% to include plaque psoriasis in pediatric patients aged 2 years and older.

HealthDay News — Clover Hill Dairy is recalling all of its brand cheese over possible Listeria contamination tied to a ...

RelabotulinumtoxinA is a liquid neuromodulator designed to deliver rapid clinical improvement in glabellar and lateral canthal lines.

Transitioning from accelerated to traditional status, the FDA's decision expands eligibility for the first solid-tumor engineered T cell therapy to include adolescents aged 12 and older.

It is increasingly recognized that galactose-deficient IgA in the glomerulus activates the alternative complement system and drives IgA nephropathy, including in the tubules and interstitium, leading ...

The table below evaluates treatment options for patients with thyroid eye disease, comparing Tepezza ® (teprotumumab-trbw) and Lumvoa ™ (veligrotug-vvze). Feature/Clinical Parameter Tepezza ® ...